- ISIN
- US49721T1016
- CUSIP
- 49721T101
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jul 31, 2015
Highlights
- Market Cap
- $11.19M
- Enterprise Value
- $784.91K
- EPS (TTM)
- -$2.66
- Gross Profit (TTM)
- -$48.74K
- EBITDA (TTM)
- -$7.38M
- Year Range
- $1.76 - $3.39
- ROA (TTM)
- -52.10%
- ROE (TTM)
- -79.37%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
KPRX Performance Chart
Kiora Pharmaceuticals, Inc. (KPRX) is up 36.0% since the beginning of the year. At $3 per share, KPRX is trading 20.9% below its 52-week high of $3. Investors who bought $1,000 worth of KPRX shares 5 years ago would now be looking at an investment worth $2.
Loading charts...
Returns By Period
Kiora Pharmaceuticals, Inc. (KPRX) has returned 36.04% so far this year and -31.28% over the past 12 months. Over the last ten years, KPRX has returned -58.68% per year, falling short of the S&P 500 Index benchmark, which averaged 13.66% annually.
Kiora Pharmaceuticals, Inc.
- 1D
- -1.47%
- 1M
- 5.51%
- YTD
- 36.04%
- 6M
- 27.62%
- 1Y
- -31.28%
- 3Y*
- -29.23%
- 5Y*
- -72.07%
- 10Y*
- -58.68%
Benchmark (S&P 500 Index)
- 1D
- -0.74%
- 1M
- 4.90%
- YTD
- 10.35%
- 6M
- 10.28%
- 1Y
- 26.52%
- 3Y*
- 20.83%
- 5Y*
- 12.30%
- 10Y*
- 13.66%
KPRX Monthly Returns History
Based on dividend-adjusted daily data since Jul 31, 2015, KPRX's average daily return is -0.11%, while the average monthly return is -3.67%.
Historically, 34% of months were positive and 66% were negative. The best month was Feb 2016 with a return of +111.8%, while the worst month was Jun 2023 at -69.2%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 7 months.
On a daily basis, KPRX closed higher 43% of trading days. The best single day was Feb 21, 2017 with a return of +125.6%, while the worst single day was Jun 2, 2023 at -49.6%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 21.83% | -12.92% | -7.66% | 21.76% | 14.04% | -0.00% | 36.04% | ||||||
| 2025 | 22.12% | -19.35% | -7.38% | 6.98% | -7.45% | -3.36% | -9.72% | 6.92% | -0.00% | -16.91% | -14.29% | -0.51% | -40.30% |
| 2024 | 5.74% | 21.47% | 5.22% | -28.81% | -1.91% | -5.34% | 10.24% | -20.09% | -1.08% | -1.09% | -9.94% | 1.23% | -29.81% |
| 2023 | 2.92% | 26.06% | -24.94% | 32.93% | -52.93% | -69.24% | -7.30% | -16.46% | 14.02% | 3.93% | -12.32% | 0.99% | -84.77% |
| 2022 | -49.01% | -18.83% | -0.42% | -14.85% | -16.98% | 6.95% | -68.74% | 32.15% | -20.91% | 6.83% | -45.97% | -3.38% | -94.32% |
| 2021 | 27.99% | -12.20% | -10.11% | -15.06% | 3.78% | -17.08% | -30.77% | -26.98% | 22.28% | -15.56% | -20.53% | 0.00% | -69.37% |
Benchmark Metrics
Kiora Pharmaceuticals, Inc. has an annualized alpha of -31.96%, beta of 0.83, and R2 of 0.02 versus S&P 500 Index. Calculated based on daily prices since August 03, 2015.
- This stock participated in 195.67% of S&P 500 Index downside but only -98.05% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.02 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -31.96%
- Beta
- 0.83
- R²
- 0.02
- Upside Capture
- -98.05%
- Downside Capture
- 195.67%
Return for Risk
Risk / Return Rank
KPRX ranks 20 for risk / return — below 20% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Kiora Pharmaceuticals, Inc. (KPRX) and compare them to S&P 500 Index.
| KPRX | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.72 | ||
| Sortino ratioReturn per unit of downside risk | -3.49 | ||
| Omega ratioGain probability vs. loss probability | 0.95 | 1.41 | -0.46 |
| Calmar ratioReturn relative to maximum drawdown | -0.68 | 2.93 | -3.61 |
| Martin ratioReturn relative to average drawdown | -1.09 | 13.52 | -14.61 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Kiora Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Kiora Pharmaceuticals, Inc. was 100.00%, occurring on Nov 20, 2025. The portfolio has not yet recovered.
The current Kiora Pharmaceuticals, Inc. drawdown is 99.99%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 bear market2025 | -100.00%Nov 2025 | 10y 3mo | — | 10y 10moAug 2015 - now |
Drawdown Indicators
| KPRX | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -100.00% | -56.78% | -43.22% |
Max Drawdown (1Y)Largest decline over 1 year | -46.11% | -9.10% | -37.01% |
Max Drawdown (3Y)Largest decline over 3 years | -76.47% | -18.90% | -57.57% |
Max Drawdown (5Y)Largest decline over 5 years | -99.89% | -25.43% | -74.46% |
Max Drawdown (10Y)Largest decline over 10 years | -99.99% | -33.92% | -66.07% |
Current DrawdownCurrent decline from peak | -99.99% | -0.74% | -99.25% |
Average DrawdownAverage peak-to-trough decline | -91.09% | -10.72% | -80.37% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 38.21% | 1.97% | +36.24% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Kiora Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Kiora Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for KPRX in comparison with other companies in the Biotechnology industry. Currently, KPRX has a P/B value of 0.8. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with KPRX
Add Kiora Pharmaceuticals, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with KPRX